Literature DB >> 26239977

Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.

Dario Lehoux1, Valerie Ostiguy2, Cordelia Cadieux2, Mireille Malouin2, Odette Belanger2, Adel Rafai Far2, Thomas R Parr2.   

Abstract

The pharmacokinetics and bone concentrations of oritavancin were investigated after a single intravenous dose was administered to rabbits. The pharmacokinetic profile of oritavancin in rabbits showed that it is rapidly distributed to bone tissues, with concentrations remaining stable for up to 168 h, the last measured time point. Based on these findings, further evaluation of oritavancin for the treatment of infections in bone tissues is warranted.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26239977      PMCID： PMC4576084          DOI： 10.1128/AAC.00981-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  Methicillin-resistant Staphylococcus aureus on orthopaedic wards: incidence, spread, mortality, cost and control.

Authors:  M Nixon; B Jackson; P Varghese; D Jenkins; G Taylor
Journal:  J Bone Joint Surg Br       Date:  2006-06

2.  Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.

Authors:  Eric G Solon; James A Dowell; Jonghui Lee; S Peter King; Bharat D Damle
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

3.  Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.

Authors:  A Saleh-Mghir; A Lefort; Y Petegnief; S Dautrey; J M Vallois; D Le Guludec; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; J R Aeschlimann; H H Houlihan; R C Mercier; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.

Authors:  C M Rubino; S M Bhavnani; G Moeck; S E Bellibas; P G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

6.  Determination of vancomycin related substances by gradient high-performance liquid chromatography.

Authors:  E L Inman
Journal:  J Chromatogr       Date:  1987-12-11

7.  Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection.

Authors:  Carole J Boylan; Kristina Campanale; Philip W Iversen; Diane L Phillips; Michael L Zeckel; Thomas R Parr
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

8.  Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.

Authors:  A Lefort; A Saleh-Mghir; L Garry; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

9.  Efficacy of teicoplanin and autoradiographic diffusion pattern of [14C]teicoplanin in experimental Staphylococcus aureus infection of joint prostheses.

Authors:  A Saleh Mghir; A C Crémieux; R Bleton; F Ismael; M Manteau; S Dautrey; L Massias; L Garry; N Sales; B Mazière; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.

Authors:  Carmen Cabellos; Antonio Fernàndez; Jose M Maiques; Fe Tubau; Carmen Ardanuy; Pedro F Viladrich; Josefina Liñares; Francesc Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191
View more
  5 in total

Review 1.  New Innovations in the Treatment of PJI and Biofilms-Clinical and Preclinical Topics.

Authors:  Mariam Taha; Hesham Abdelbary; F Patrick Ross; Alberto V Carli
Journal:  Curr Rev Musculoskelet Med       Date:  2018-09

2.  Continued Dosing of Oritavancin for Complicated Gram-Positive Infections.

Authors:  Jodi Meyer; Paul Lata; Susanne Barnett
Journal:  Fed Pract       Date:  2020-11

3.  Long-Acting Lipoglycopeptides: "Lineless Antibiotics" for Serious Infections in Persons Who Use Drugs.

Authors:  Taylor Morrisette; Matthew A Miller; Brian T Montague; Gerard R Barber; R Brett McQueen; Martin Krsak
Journal:  Open Forum Infect Dis       Date:  2019-06-05       Impact factor: 3.835

Review 4.  Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.

Authors:  Karrine D Brade; Jeffrey M Rybak; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2016-02-01

5.  Orthopaedic Implant-Associated Staphylococcal Infections: A Critical Reappraisal of Unmet Clinical Needs Associated with the Implementation of the Best Antibiotic Choice.

Authors:  Milo Gatti; Simona Barnini; Fabio Guarracino; Eva Maria Parisio; Michele Spinicci; Bruno Viaggi; Sara D'Arienzo; Silvia Forni; Angelo Galano; Fabrizio Gemmi
Journal:  Antibiotics (Basel)       Date:  2022-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.